Subcutaneous administration of liraglutide ameliorates alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes

Journal of Alzheimer's Disease

Volumn 37, Issue 3, 2013, Pages 637-648

  Yang, Yan ^a   Zhang, Jing ^a   Ma, Delin ^a   Zhang, Muxun ^a   Hu, Shuhong ^a   Shao, Shiying ^a   Gong, Cheng Xin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

AKT; Alzheimer's disease; GLP 1 agonist; GSK 3 ; insulin; liraglutide; tau phosphorylation; type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; LIRAGLUTIDE; PROTEIN KINASE B; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN TISSUE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; TREATMENT OUTCOME; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, WISTAR; TAU PROTEINS;

EID: 84890808796     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130491     Document Type: Article

References (50)

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wis-niewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
2. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
3. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. Neuro-molecular Med 12, 1-12.
4. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
5. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tanglesin Alzheimer's disease. Ann Neurol 41, 17-24.
6. Mackay EA, Ehrhard A, Moniatte M, Guenet C, Tardif C, Tarnus C, Sorokine O, Heintzelmann B, Nay C, Remy JM, Higaki J, Van Dorsselaer A, Wagner J, Danzin C, Mamont P (1997) A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur J Biochem 244, 414-425.
7. Han W, Li C (2010) Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci USA 107, 6557-6558.
8. Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 9, 617-630.
9. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362, 1090-1101.
10. Kopf D, Frolich L (2009) Risk ofincident Alzheimer's disease in diabetic patients: A systematic review of prospective trials. J Alzheimers Dis 16, 677-685.
11. Park SA (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: Evidence from animal models. J Clin Neurol 7, 10-18.
12. Boado RJ, Zhang Y, Pardridge WM (2007) Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 96, 381-391.
13. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease? Ageing Res Rev 10, 264-273.
14. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225, 54-62.
15. Rhein V, Eckert A (2007) Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function-role of glucose metabolism and insulin signalling. Arch Physiol Biochem 113, 131-141.
16. Hoyer S (2002) The aging brain, Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm 109, 991-1002.
17. Jolivalt CG, Calcutt NA, Masliah E (2012) Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease. Neuroscience 202, 405-412.
18. Gao C, Holscher C, Liu Y, Li L (2012) GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 23, 1-11.
19. Jendle J, Martin SA, Milicevic Z (2012) Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: A critical review. Expert Opin Investig Drugs 21, 1463-1474.
20. Holscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84, 331-354.
21. Belsham DD, Fick LJ, Dalvi PS, Centeno ML, Chalmers JA, Lee PK, Wang Y, Drucker DJ, Koletar MM (2009) Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J 23, 4256-4265.
22. Iwai T, Suzuki M, Kobayashi K, Mori K, Mogi Y, Oka J (2009) The influences of juvenile diabetes on memory and hippocampal plasticityin rats: Improving effects of glucagon-like peptide-1. Neurosci Res 64, 67-74.
23. Abbas T, Faivre E, Holscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 205, 265-271.
24. Han WN, Holscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS (2013) Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 34, 576-588.
25. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sam-bamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19, 1205-1219.
26. Hunter K, Holscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13, 33.
27. Hoistad M, Samskog J, Jacobsen KX, Olsson A, Hansson HA, Brodin E, Fuxe K (2005) Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res 1041, 167-180.
28. McClean PL, Parthsarathy V, Faivre E, Holscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31, 6587-6594.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis modelassessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
30. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111, 242-249.
31. Yang Y, Hu S, Zhang J, Zhang M, Gong C (2006) Alzheimerlike hyperphosphorylation of tau in brains of rats with obesity and type 2 diabetes. Prog Biochem Biophys 33, 458-464.
32. Yang Y, Ma D, Wang Y, Jiang T, Hu S, Zhang M, Yu X, Gong CX (2013) Intranasal insulin ameliorates tau hyperphospho-rylation in a rat model of type 2 diabetes. J Alzheimers Dis 33, 329-338.
33. Popkie AP, Zeidner LC, Albrecht AM, D'Ippolito A, Eckardt S, Newsom DE, Groden J, Doble BW, Aronow B, McLaughlin KJ, White P, Phiel CJ (2010) Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem 285, 41337-41347.
34. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85, 148-175.
35. Gong CX, Grundke-Iqbal I, Iqbal K (2010) Targeting tau protein in Alzheimer's disease. Drugs Aging 27, 351-365.
36. delaMonte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 9, 35-66.
37. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C (2012) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med 15, 102-114.
38. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neu-rosci 27, 13635-13648.
39. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
40. Stein MS, Scherer SC, Ladd KS, Harrison LC (2011) A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulininAlzheimer's disease. J Alzheimers Dis 26, 477-484.
41. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment:Apilot clinical trial. Arch Neurol69, 29-38.
42. Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321-2328.
43. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Phosphatase activity toward abnormally phosphory-lated tau: Decrease in Alzheimer disease brain. J Neurochem 65, 732-738.
44. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
45. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
46. Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28, 2624-2632.
47. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 101, 10804-10809.
48. Liu F, Shi J, Tanimukai H, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathologyinAlzheimer's disease. Brain 132, 1820-1832.
49. Avila J, Hernandez F (2007) GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7, 1527-1533.
50. Takashima A (2009) Drug development targeting the glyco-gen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: Role of GSK-3beta in adult brain. J Pharmacol Sci 109, 174-178.